The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.
 
Apostolia Maria Tsimberidou
Honoraria - Covance; Genentech
Consulting or Advisory Role - Tempus
Research Funding - Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Lilly; Merck; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Pei Hsu
Employment - OBI Pharma
 
I-Ju Chen
Employment - OBI Pharma
 
Tillman E. Pearce
Employment - OBI Pharma